Amplia Therapeutics Limited CEO and MD, Dr Chris Burns was interviewed by The Market Herald’s Fouad Haidar on The Watchlist, to discuss the Company’s R&D activities, and progress on the ACCENT trial in pancreatic cancer patients.
Click here to take a look.
